CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$3.14 USD
-0.33 (-9.51%)
Updated Jun 10, 2024 03:59 PM ET
After-Market: $3.14 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
F Value B Growth A Momentum C VGM
Brokerage Reports
CASI Pharmaceuticals Inc. [CASI]
Reports for Purchase
Showing records 21 - 40 ( 70 total )
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
New drug licensed targeting antibody checkpoints
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Evomela supply secured, CNCT19 on track
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Manufacturer Switch Completed; Expect Ramp-Up in 2H20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Evomela Sales Beats Expectations Despite COVID-19 Challenges; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Aiming to be China?s hematology company
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Evomela Launch Continues the Momentum; Lower $3.50 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Strong Start for Evomela Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Expanding Oncology Portfolio With Octreotide; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Evomela Launched in China; an Expanded Oncology Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Evomela to Launch in 2H19; New CD38 Product Ready for Phase 1; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S